Monte Rosa Therapeutics(GLUE) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wells Fargo Maintains Equal-Weight on Monte Rosa Therapeutics, Lowers Price Target to $10
Benzinga45minutes ago · Ratings
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Raises Price Target to $17
BenzingaMar 21 10:25 ET · Ratings
Monte Rosa Therapeutics Analyst Ratings
BenzingaMar 21 10:24 ET · Ratings
Wedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
TipRanksMar 21 08:27 ET · Ratings
Wells Fargo Reaffirms Their Hold Rating on Monte Rosa Therapeutics (GLUE)
TipRanksMar 21 05:16 ET · Ratings
Express News | Monte Rosa Therapeutics Inc : Wedbush Raises Target Price to $17 From $15
ReutersMar 21 00:04 ET

Comments

Jaguar8

Feb 4 12:41

🟡 Watchlist, FEBRUARY 4,2025, Tuesday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...

77

22

4

Jaguar8

Feb 3 07:52

🟢 Watchlist, FEBRUARY 3,2025, Monday. NFA. (Do not comment on stocks not on list or you get automatically BLOCKED) -DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...

40

9

4

Trytosaveabit

Dec 11, 2024 20:52

Just a bit from the licensing agreement! Hehehe.

$Monte Rosa Therapeutics (GLUE.US)$ Novartis has agreed to pay Monte Rosa $150 million up front. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT...

1

Trytosaveabit

Dec 11, 2024 20:26

Update! Watching for data! Today is Day 2!

$Monte Rosa Therapeutics (GLUE.US)$ Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio Breast Cancer Symposium

Trytosaveabit

Dec 11, 2024 20:10

Update

$Monte Rosa Therapeutics (GLUE.US)$ Reuters· 9 mins ago
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-Modulating Vav1-Directed Molecular Glue Degraders

GLUE Monte Rosa Therapeutics

Trade Overview

Capital Trend

News

Comments